Immunotherapy for head and neck cancer: where do we go from here?

被引：0
作者：
Ko, Eric C. [1 ]
Hanna, Glenn J. [2 ]
机构：
[1] Univ Massachusetts, UMass Mem Med Ctr, Chan Med Sch, Dept Radiat Oncol, 55 Lake Ave North, Worcester, MA 01655 USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Ctr Head & Neck Oncol, 450 Brookline Ave, Boston, MA 02215 USA
来源：
IMMUNOTHERAPY | 2023年
关键词：
cancer immunology; checkpoint inhibitors; head and neck squamous cell cancer; immunotherapy; radiotherapy; SQUAMOUS-CELL CARCINOMA; OPEN-LABEL; PEMBROLIZUMAB; CETUXIMAB; RECURRENT; CHEMOTHERAPY; MULTICENTER; NIVOLUMAB; CARE;
D O I：
10.2217/imt-2023-0191
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Immunotherapy for head and neck cancer shows promising new directions - and challenges ahead. What can we learn from recent trials to improve patient selection and optimize combination therapy?
引用
收藏
页码：1497 / 1500
页数：4
相关论文
共 50 条
  • [41] Treatment strategy after the discontinuation of immunotherapy for head and neck cancer: a review
    Wakasugi, Tetsuro
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2023, 9
  • [42] Immunotherapy in head and neck cancer: aiming at EXTREME precision
    Petr Szturz
    Jan B. Vermorken
    BMC Medicine, 15
  • [43] Integrating Immunotherapy into Multimodal Treatment of Head and Neck Cancer
    Rao, Yuan James
    Goodman, Joseph F.
    Haroun, Faysal
    Bauman, Julie E.
    CANCERS, 2023, 15 (03)
  • [44] The value of immunotherapy in head and neck cancer
    Manca, Paolo
    Raez, Luis E.
    Salzberg, Matthew
    Sanchez, Jorge
    Hunis, Brian
    Rolfo, Christian
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (01) : 35 - 43
  • [45] Research progress of immunotherapy for advanced head and neck cancer
    Sun, Anchi
    Xing, Zhiwei
    Lv, Rongrong
    Niu, Pengyuan
    Zhao, Bao
    Ma, Shiyin
    Li, Hui
    MEDICAL ONCOLOGY, 2024, 41 (06)
  • [46] Financial Incentives and Maternal Health: Where Do We Go from Here?
    Morgan, Lindsay
    Stanton, Mary Ellen
    Higgs, Elizabeth S.
    Balster, Robert L.
    Bellows, Ben W.
    Brandes, Neal
    Comfort, Alison B.
    Eichler, Rena
    Glassman, Amanda
    Hatt, Laurel E.
    Conlon, Claudia M.
    Koblinsky, Marge
    JOURNAL OF HEALTH POPULATION AND NUTRITION, 2013, 31 (04) : 8 - 22
  • [47] Self-tracking the microbiome: where do we go from here?
    Gimbert, Carine
    Lapointe, Francois-Joseph
    MICROBIOME, 2015, 3 : 70
  • [48] Immunotherapy for Prostate Cancer: Where Do We Go From Here? PART 2: Checkpoint Inhibitors, Immunotherapy Combinations, Tumor Microenvironment Modulation, and Cellular Therapies
    Patel, Amar
    Fong, Lawrence
    ONCOLOGY-NEW YORK, 2018, 32 (06): : E65 - E73
  • [49] Revisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy
    Smussi, Davide
    Mattavelli, Davide
    Paderno, Alberto
    Gurizzan, Cristina
    Lorini, Luigi
    Romani, Chiara
    Bignotti, Eliana
    Grammatica, Alberto
    Ravanelli, Marco
    Bossi, Paolo
    CANCER TREATMENT REVIEWS, 2023, 121
  • [50] Metabolic targeting, immunotherapy and radiation in locally advanced non-small cell lung cancer: Where do we go from here?
    Dhawan, Annika
    Pifer, Phillip M. M.
    Sandulache, Vlad C. C.
    Skinner, Heath D. D.
    FRONTIERS IN ONCOLOGY, 2022, 12
12345